WO2005025488A3 - Methods for the controlled delivery of pharmacologically active compounds - Google Patents

Methods for the controlled delivery of pharmacologically active compounds Download PDF

Info

Publication number
WO2005025488A3
WO2005025488A3 PCT/US2004/011823 US2004011823W WO2005025488A3 WO 2005025488 A3 WO2005025488 A3 WO 2005025488A3 US 2004011823 W US2004011823 W US 2004011823W WO 2005025488 A3 WO2005025488 A3 WO 2005025488A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacologically active
compositions
methods
present
active compounds
Prior art date
Application number
PCT/US2004/011823
Other languages
French (fr)
Other versions
WO2005025488A2 (en
Inventor
Yerramilli V S N Murthy
Robert H Suva
Original Assignee
Idexx Lab Inc
Yerramilli V S N Murthy
Robert H Suva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc, Yerramilli V S N Murthy, Robert H Suva filed Critical Idexx Lab Inc
Priority to AU2004271909A priority Critical patent/AU2004271909A1/en
Priority to BRPI0413883-0A priority patent/BRPI0413883A/en
Priority to CA002535373A priority patent/CA2535373A1/en
Priority to JP2006524614A priority patent/JP2007503433A/en
Priority to EP04816168A priority patent/EP1667654A2/en
Publication of WO2005025488A2 publication Critical patent/WO2005025488A2/en
Publication of WO2005025488A3 publication Critical patent/WO2005025488A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water immiscible solvent. In one embodiment the compositions are provided as injectable compositions. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. The compositions are released over time when administered to a mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for periods of up to 15 days or even longer. Many compounds can be administered according to the present invention, including, but not limited to, tilmicosin, oxytetracycline, fluoxetine, roxithromycin, and turbinafine.
PCT/US2004/011823 2003-08-27 2004-04-16 Methods for the controlled delivery of pharmacologically active compounds WO2005025488A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004271909A AU2004271909A1 (en) 2003-08-27 2004-04-16 Methods for the controlled delivery of pharmacologically active compounds
BRPI0413883-0A BRPI0413883A (en) 2003-08-27 2004-04-16 composition and method for administering a pharmacologically active compound to a mammal
CA002535373A CA2535373A1 (en) 2003-08-27 2004-04-16 Methods for the controlled delivery of pharmacologically active compounds
JP2006524614A JP2007503433A (en) 2003-08-27 2004-04-16 Method for the controlled delivery of pharmaceutically active compounds
EP04816168A EP1667654A2 (en) 2003-08-27 2004-04-16 Methods for the controlled delivery of pharmacologically active compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,262 2003-08-27
US10/650,262 US20050049210A1 (en) 2003-08-27 2003-08-27 Methods for the controlled delivery of pharmacologically active compounds

Publications (2)

Publication Number Publication Date
WO2005025488A2 WO2005025488A2 (en) 2005-03-24
WO2005025488A3 true WO2005025488A3 (en) 2005-05-12

Family

ID=34217115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011823 WO2005025488A2 (en) 2003-08-27 2004-04-16 Methods for the controlled delivery of pharmacologically active compounds

Country Status (7)

Country Link
US (1) US20050049210A1 (en)
EP (1) EP1667654A2 (en)
JP (1) JP2007503433A (en)
AU (1) AU2004271909A1 (en)
BR (1) BRPI0413883A (en)
CA (1) CA2535373A1 (en)
WO (1) WO2005025488A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446103B1 (en) * 2001-10-19 2015-12-23 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
CN101983632A (en) * 2010-10-11 2011-03-09 西北农林科技大学 Compound Tilmicosin nanoemulsion antibacterial agent and preparation method thereof
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
WO2014126969A1 (en) 2013-02-12 2014-08-21 Bend Research, Inc. Solid dispersions of low-water solubility actives
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CN103463480A (en) * 2013-08-22 2013-12-25 邢波 Preparation method of traditional Chinese medicine for treating axillary acute purulent lymphadenitis caused by obstruction of channels and collaterals
CN107873024A (en) * 2015-02-09 2018-04-03 塞尔利克斯生物私人有限公司 For treating the composition and method of catarrh
CN107184553A (en) * 2017-06-14 2017-09-22 天津佰力喜动物药业有限公司 A kind of preparation method of tilmicosin liposome dispersant
CN108392467A (en) * 2018-05-30 2018-08-14 山东德信生物科技有限公司 A kind of Tilmicosin injection and preparation method thereof
CN109077999A (en) * 2018-08-31 2018-12-25 田红卫 A kind of long-acting slow-release Tilmicosin injection and preparation method thereof
CN109655534B (en) * 2018-11-08 2021-11-30 佛山市正典生物技术有限公司 Method for detecting content of tilmicosin particles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28875A (en) * 1860-06-26 Improvement in desulphurizing ores and coal
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
ES8104203A1 (en) * 1979-02-05 1981-04-16 Schering Corp 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their manufacture and intermediates useful therein, methods for their use as antibacterial agents and compositions useful therefor
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4876352A (en) * 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
PL166385B1 (en) * 1990-10-25 1995-05-31 Schering Corp Method of obtaining oxazoline compound
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
ATE225666T1 (en) * 1993-11-15 2002-10-15 Celtrix Pharma USE OF IGF-1 AND IGFBP-3 FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING KIDNEY DISEASE
US6110905A (en) * 1994-07-09 2000-08-29 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US6310053B1 (en) * 1995-07-05 2001-10-30 Norbrook Laboratories Limited Long-acting oxytetracycline composition
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US5723447A (en) * 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
US5663361A (en) * 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
UA51730C2 (en) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-0-substituted ketolides having antibacterial activity
US5766506A (en) * 1996-09-12 1998-06-16 The Dow Chemical Company Hard water compatible phosphate-containing heat transfer fluids
SE511313C2 (en) * 1997-01-13 1999-09-06 Gs Dev Ab A controlled release composition comprising diacylglycerol fatty acid ester
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US5977133A (en) * 1998-08-19 1999-11-02 Abbott Laboratories Pyridone antibiotic with improved safety profile
US6174540B1 (en) * 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1446103B1 (en) * 2001-10-19 2015-12-23 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
CA2466868C (en) * 2001-12-21 2010-06-22 Shire Laboratories Inc. Oral capsule formulation with increased physical stability

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation

Also Published As

Publication number Publication date
CA2535373A1 (en) 2005-03-24
JP2007503433A (en) 2007-02-22
US20050049210A1 (en) 2005-03-03
BRPI0413883A (en) 2006-10-24
EP1667654A2 (en) 2006-06-14
WO2005025488A2 (en) 2005-03-24
AU2004271909A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2003034988A3 (en) Injectable compositions for the controlled delivery of pharmacologically active compound
WO2005025488A3 (en) Methods for the controlled delivery of pharmacologically active compounds
KR20130010473A (en) Transdermal delivery patch
AR061289A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS THAT INCLUDE FESOTERODINE
ES2253423T3 (en) FORMULATION OF A TESTOSTERONE ESTER FOR HUMAN USE.
BRPI0512177A (en) modified release formulation of memantine
BRPI0618891A2 (en) pharmaceutical compositions
MX2009013832A (en) Purine derivatives and their use as modulators of toll-like receptor 7.
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
WO2004091541A3 (en) Methods for the controlled delivery of pharmacologically active compounds
HK1176318A1 (en) Injection device
EA200501819A1 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE TESTERTERON LEVELS IN SERUM
RU2017110076A (en) PHARMACEUTICAL COMPOSITION AND METHODS
RU2017145643A (en) PHARMACEUTICAL COMPOSITIONS FOR THE PROLONGED SURVIVAL OF SEBACOIL-DINALBUFIN ETHER
WO2007099410A3 (en) Formulations of fispemifene
JP2007503433A5 (en)
WO2015095045A1 (en) Long-acting ketoprofen compositions
WO2007117581A3 (en) Stabilized transdermal bupropion preparations
AR045576A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND ETHYLESTRADIOL
CN102085199B (en) Percutaneous absorption biological patch for treating rheumatoid arthritis and preparing method thereof
PE20020903A1 (en) METHOD TO PREVENT DIARRHEA
JP2005532336A5 (en)
WO2021035086A1 (en) Solvent delivery system for topical delivery of active agents
WO2010019279A8 (en) Pharmaceutical compositions configured to deter dosage form splitting
BRPI0506710A (en) controlled release pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2535373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006524614

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004271909

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004271909

Country of ref document: AU

Date of ref document: 20040416

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004816168

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004816168

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413883

Country of ref document: BR